Fjarde AP Fonden Fourth Swedish National Pension Fund Has $4.49 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in Teva Pharmaceutical Industries by 6.2%, now holding 291,804 shares valued at $4.49 million.
• Several institutional investors increased their stakes in Teva, with Russell Investments Group Ltd. raising its holding by 30% to a total of 265,777 shares.
• Research analysts have recently upgraded Teva’s stock, with JPMorgan raising its rating to "overweight" and setting a price target of $23.00.

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 6.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,804 shares of the company's stock after selling 19,339 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Teva Pharmaceutical Industries were worth $4,485,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $44,000. Golden State Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $39,000. New Age Alpha Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Compagnie Lombard Odier SCmA purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth $54,000. Finally, Capital Analysts LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $102,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 2.8%

Shares of NYSE TEVA traded down $0.5050 during trading hours on Tuesday, hitting $17.5550. The stock had a trading volume of 12,485,740 shares, compared to its average volume of 12,708,362. The company has a market capitalization of $20.13 billion, a P/E ratio of -109.72, a P/E/G ratio of 1.07 and a beta of 0.62. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The firm's 50-day moving average price is $16.69 and its two-hundred day moving average price is $16.25. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company's revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Activity

In other news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares of the company's stock, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 65,001 shares of company stock valued at $996,958. 0.55% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TEVA. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target on the stock. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.